IgG4-related DiseaseNCT07793903
BCT301 in Treating Refractory/Recurrent IgG4-related Disease
A study testing BCT301 Cell Injection in people with IgG4-related Disease, run by Peking University Third Hospital.
Trial summary
This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- IgG4-related Disease
- What is being tested?
- BCT301 Cell Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- No sites listed yet
- Study dates
- Oct 2026to Feb 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntarily participate in this trial and sign the informed consent form;
- Male or female patients aged 18 to 75 years (inclusive), with body weight ≥ 40 kg;
- Women of childbearing potential must have a negative serum pregnancy test before the start of the trial and agree to use effective contraception during the trial and until the last follow-up; male subjects whose partners are of childbearing potential agree to use effective contraception during the trial and until the last follow-up;
- Confirmed diagnosis of IgG4-related disease meeting the classification criteria for IgG4-RD (the 2020 updated version of the comprehensive diagnostic criteria for IgG4-RD established in Japan) or the 2019 ACR/EULAR classification criteria for IgG4-RD; and with at least one of the following organ involvements: pancreas, bile ducts, kidneys, lungs, heart or pericardium, aorta and great vessels, retroperitoneal fibrosis, sclerosing mediastinitis, dura mater, or pituitary gland;
- Clinically meets the criteria for refractory/recurrent IgG4-RD: disease remains active, or relapses after remission, or progresses despite systemic treatment with standard-of-care regimens-glucocorticoids, immunosuppressants (cyclophosphamide, mycophenolate mofetil, methotrexate, azathioprine, etc.)-or biologic agents;
- Currently receiving one or more of the following stable-dose standard therapies:
Show all 17Show fewer
- If the patient is receiving glucocorticoid therapy, the following conditions must be met: at screening and during the screening period, the maximum glucocorticoid dose is 30 mg/day of prednisone (or equivalent). The glucocorticoid dose must remain stable for ≥ 7 days prior to screening; during the screening period, glucocorticoid dose adjustments must not exceed 5 mg/day of prednisone (or equivalent);
- If the patient is receiving immunomodulators/immunosuppressants: initiation of drug therapy must be ≥ 12 weeks prior to screening. A stable drug dose must be maintained for ≥ 4 weeks prior to screening and during the screening period;
- If biologic agents (e.g., belimumab or telitacicept) were used before the screening period, they must be discontinued for at least 5 half-lives before screening; if anti-CD20 monoclonal antibody therapy was used before the screening period, an interval of 6 months is required before screening;
- IgG4-RD Responder Index (RI) ≥ 2, with disease in an active state;
- Peripheral blood B cells show positive CD19 expression by flow cytometry;
- Major organ function must meet the following requirements (conditions caused by the immune disease itself are exempt):
- Bone marrow hematopoietic function must meet: a. White blood cell count ≥ 3 × 10^9/L; b. Neutrophil count ≥ 1 × 10^9/L (no colony-stimulating factor treatment within 2 weeks prior to the examination); c. Hemoglobin ≥ 70 g/L;
- Hepatic function: Alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≤ 3 × ULN, total bilirubin (TBIL) ≤ 2 × ULN (excluding Gilbert syndrome, for which total bilirubin ≤ 3.0 × ULN);
- Renal function: Creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula);
- Coagulation function: International normalized ratio (INR) < 1.5 × ULN, prothrombin time (PT) < 1.5 × ULN;
- Cardiac function: Good hemodynamic stability.
Who cannot join
- The patient must not participate in this study if any of the following criteria are met:
- 1) Diseases that, after evaluation by the investigator, are considered inappropriate for participation in this study, for example life-threatening conditions;
- 2) Reduced organ functional reserve not caused by the primary disease:
- Neutrophil count < 1 × 10^9/L; lymphocyte count < 0.3 × 10^9/L; hemoglobin < 70 g/L; platelet count < 50 × 10^9/L;
- ALT > 3 × ULN; AST > 3 × ULN; total bilirubin > 2 × ULN;
- Creatinine clearance < 40 mL/min, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m², or serum creatinine > 2.5 mg/dL;
Show all 21Show fewer
- Left ventricular ejection fraction ≤ 45% as diagnosed by echocardiography;
- Blood oxygen saturation ≤ 92%;
- 3) History of alcohol abuse or drug abuse within the past 24 weeks;
- 4) History of malignancy other than B-cell lymphoma within the past 5 years (excluding non-melanoma skin cancer, surgically cured cervical cancer, etc.);
- 5) Presence of infection with human immunodeficiency virus (HIV), agammaglobulinemia, T-cell deficiency virus, syphilis, chronic hepatitis B or C, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.;
- 6) Known active tuberculosis (TB) infection or bacterial infection;
- 7) History of myocardial infarction, coronary angioplasty or stent placement, unstable angina, active arrhythmia, or other clinically significant cardiac disease requiring clinical intervention within 6 months before the start of screening;
- 8) History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months before the start of screening;
- 9) Known severe allergic reactions to cell-therapy-related components or their excipients, or to other immunotherapeutic agents;
- 10) Prior organ transplantation requiring long-term immunosuppressive medication;
- 11) Known simultaneous participation in other clinical trials affecting the disease or treatment;
- 12) Prior treatment with CD19- and/or BCMA-targeted therapy or any CAR-T cell product targeting any antigen; unless, as assessed by the investigator, the prior treatment has clearly failed (including failure to achieve remission after treatment, remission duration below the required standard, or disease progression), the current disease state is suitable for treatment in this study, and there is no clear evidence that toxicity related to prior treatment may affect the safety of this study;
- 13) Severe psychiatric illness and severe cognitive impairment;
- 14) Pregnant or lactating women, or women planning pregnancy;
- 15) Any condition considered by the investigator to be inappropriate for enrollment in this clinical trial.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Clinical Study to Evaluate the Safety and Efficacy of BCT301 Cell Injection in Patients With Refractory/Recurrent IgG4-Related Disease
This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease.
Read the detailed description
This is a single-arm, open-label, single-center clinical study in which all patients receive a unified treatment regimen. The primary objective is to evaluate the safety and tolerability of BCT301 Cell Injection in patients with refractory/recurrent IgG4-RD. Secondary objective is to evaluate the improvement in disease activity in patients with refractory/recurrent IgG4-RD treated with BCT301 Cell Injection. Six subjects with refractory/recurrent IgG4-RD meeting the inclusion/exclusion criteria are planned to be enrolled and will receive a single infusion of 1.8 × 10^8 BCT301 Cell Injection to evaluate the safety, efficacy, and PK/PD characteristics following BCT301 Cell Injection infusion. The study flow consists of a screening period, a lymphodepletion pretreatment period, a treatment period, and a follow-up period. Patients without relapse or deterioration after BCT301 Cell Injection infusion and not requiring protocol-prohibited treatment will undergo a primary follow-up of up to 360 days.
- Conditions
- IgG4-related Disease
- Being tested
- BCT301 Cell Injection
- Medical subject headings
- Immunoglobulin G4-Related Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BCT301 Cell InjectionOther
BCT301 Cell Injection are CAR-iT cells derived from chemically induced pluripotent stem cells. Six subjects with refractory/recurrent IgG4-RD meeting the inclusion/exclusion criteria are planned to be enrolled and will receive a single infusion of 1.8 × 10^8 BCT301 Cell Injection to evaluate the safety, efficacy, and PK/PD characteristics following BCT301 Cell Injection infusion.
| Study group | Role | What they receive |
|---|---|---|
| BCT301 Cell Injection therapy group | Experimental | Not described Receives: Other: BCT301 Cell Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
The safety and tolerability of BCT301 Cell Injection in patients with refractory/recurrent IgG4-RD.
The occurrence of cell-infusion-related adverse events within 28 days after BCT301 Cell Injection infusion, with special emphasis on cell-therapy-specific adverse reactions such as CRS and ICANS.
Measured: 28 days after BCT301 Cell Injection infusion
Secondary outcomes (6)
The change in IgG4-RD RI from baseline at 180 days after BCT301 Cell Injection infusion.
This endpoint evaluates the absolute change in the IgG4-Related Disease Responder Index (IgG4-RD RI) score from baseline to Day 180 post-infusion. The IgG4-RD RI is a validated, disease-specific composite scoring system that quantifies organ involvement and disease activity across multiple domains (e.g., head/neck, chest, retroperitoneum, etc.). The change is calculated as the Day 180 score minus the baseline score; a negative value indicates improvement (reduction in disease activity), while a positive value indicates worsening. This continuous variable complements the binary response rate endpoint by providing a more granular assessment of the degree of clinical improvement or deterioration over time, and will be analyzed using descriptive statistics (mean, median, standard deviation) as well as inferential tests (e.g., paired t-test or Wilcoxon signed-rank test) for within-subject change.
Measured: 180 days after BCT301 Cell Injection infusion.
IgG4-RD RI response rate (decrease ≥ 2 points from baseline) at 90 and 180 days after BCT301 Cell Injection infusion.
This endpoint measures the proportion of subjects achieving at least a 2-point reduction from baseline in the IgG4-Related Disease Responder Index (IgG4-RD RI) at Day 90 and Day 180 post-infusion. The IgG4-RD RI is a validated disease activity scoring system; a decrease of ≥2 points is considered clinically meaningful and indicates a partial response to treatment.
Measured: 90, 180 days after BCT301 Cell Injection infusion.
IgG4-RD complete remission rate at 180 and 360 days after BCT301 Cell Injection infusion.
This endpoint evaluates the proportion of subjects who achieve stringent complete remission at Day 180 and Day 360. Complete remission requires all three criteria to be met simultaneously: (1) IgG4-RD RI score of 0 (no active disease manifestations); (2) prednisone dose of 0 mg/day after Week 4 (excluding any short-term glucocorticoid pulse used specifically to manage cytokine release syndrome [CRS] or allogeneic immune reactions, which are not counted as maintenance therapy); and (3) no documented recurrence or flare of disease activity from baseline through the assessment time point.
Measured: 180 and 360 days after BCT301 Cell Injection infusion.
Proportion of patients with relapse after remission at 90, 180, and 360 days after BCT301 Cell Injection infusion.
This endpoint measures the cumulative proportion of subjects who, having achieved any remission (partial or complete) after infusion, subsequently experience disease relapse at Day 90, Day 180, or Day 360. Relapse is specifically defined as an increase in IgG4-RD RI score during the follow-up period that necessitates additional therapeutic intervention not specified in the study protocol, thereby indicating loss of disease control.
Measured: 90, 180, and 360 days after BCT301 Cell Injection infusion.
Changes in IgG4 levels at 90, 180, and 360 days after BCT301 Cell Injection infusion.
This endpoint assesses the absolute change from baseline in serum IgG4 concentration (measured in g/L) at Day 90, Day 180, and Day 360 post-infusion.
Measured: 90, 180, and 360 days after BCT301 Cell Injection infusion.
Physician Global Assessment (PhGA) and Patient Global Assessment (PtGA) compared with baseline.
This endpoint evaluates the change from baseline in both the Physician Global Assessment (PhGA) and the Patient Global Assessment (PtGA), each measured using a single-item visual analogue scale (VAS) ranging from 0 to 100 mm, where 0 indicates no disease activity and 100 indicates the worst possible disease activity/symptoms. Higher scores indicate a worse outcome. Changes are assessed at predefined time points (consistent with other endpoints, e.g., 90, 180, and 360 days) to capture the treatment effect from both clinician and patient perspectives.
Measured: 90, 180, and 360 days after BCT301 Cell Injection infusion.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2026
- Study startOct 2026 (estimated)
- Primary completionJun 2028 (estimated)
- Study completionFeb 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IgG4-related DiseaseStudies of the same condition, open and under way.
- More trials run by Peking University Third HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 6 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mu Rong, Peking University Third Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07793903
- Sponsor's protocol ID
- BCT301-IIT-02
- Status last verified
- Aug 2026
- First submitted
- 16 Aug 2026
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study to Evaluate the Safety and Efficacy of BCT301 Cell Injection in Patients With Refractory/Recurrent IgG4-Related Disease
- ClinicalTrials.gov ID
- NCT07793903
- Acronym / sponsor ID
- BCT301-IIT-02
- Conditions
- IgG4-related Disease
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 6 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Study start
- Oct 2026 (estimated)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Feb 2030 (estimated)
- First posted
- 31 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease.
Detailed description
This is a single-arm, open-label, single-center clinical study in which all patients receive a unified treatment regimen. The primary objective is to evaluate the safety and tolerability of BCT301 Cell Injection in patients with refractory/recurrent IgG4-RD. Secondary objective is to evaluate the improvement in disease activity in patients with refractory/recurrent IgG4-RD treated with BCT301 Cell Injection. Six subjects with refractory/recurrent IgG4-RD meeting the inclusion/exclusion criteria are planned to be enrolled and will receive a single infusion of 1.8 × 10^8 BCT301 Cell Injection to evaluate the safety, efficacy, and PK/PD characteristics following BCT301 Cell Injection infusion. The study flow consists of a screening period, a lymphodepletion pretreatment period, a treatment period, and a follow-up period. Patients without relapse or deterioration after BCT301 Cell Injection infusion and not requiring protocol-prohibited treatment will undergo a primary follow-up of up to 360 days.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| BCT301 Cell Injection therapy group | Experimental | Other: BCT301 Cell Injection |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Voluntarily participate in this trial and sign the informed consent form;
- Male or female patients aged 18 to 75 years (inclusive), with body weight ≥ 40 kg;
- Women of childbearing potential must have a negative serum pregnancy test before the start of the trial and agree to use effective contraception during the trial and until the last follow-up; male subjects whose partners are of childbearing potential agree to use effective contraception during the trial and until the last follow-up;
- Confirmed diagnosis of IgG4-related disease meeting the classification criteria for IgG4-RD (the 2020 updated version of the comprehensive diagnostic criteria for IgG4-RD established in Japan) or the 2019 ACR/EULAR classification criteria for IgG4-RD; and with at least one of the following organ involvements: pancreas, bile ducts, kidneys, lungs, heart or pericardium, aorta and great vessels, retroperitoneal fibrosis, sclerosing mediastinitis, dura mater, or pituitary gland;
- Clinically meets the criteria for refractory/recurrent IgG4-RD: disease remains active, or relapses after remission, or progresses despite systemic treatment with standard-of-care regimens-glucocorticoids, immunosuppressants (cyclophosphamide, mycophenolate mofetil, methotrexate, azathioprine, etc.)-or biologic agents;
Key exclusion criteria (21 listed)
- The patient must not participate in this study if any of the following criteria are met:
- 1) Diseases that, after evaluation by the investigator, are considered inappropriate for participation in this study, for example life-threatening conditions;
- 2) Reduced organ functional reserve not caused by the primary disease:
- Neutrophil count < 1 × 10^9/L; lymphocyte count < 0.3 × 10^9/L; hemoglobin < 70 g/L; platelet count < 50 × 10^9/L;
- ALT > 3 × ULN; AST > 3 × ULN; total bilirubin > 2 × ULN;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BCT301 Cell InjectionBCT301 Cell Injection are CAR-iT cells derived from chemically induced pluripotent stem cells. Six subjects with refractory/recurrent IgG4-RD meeting the inclusion/exclusion criteria are planned to be enrolled and will receive a single infusion of 1.8 × 10^8 BCT301 Cell Injection to evaluate the safety, efficacy, and PK/PD characteristics following BCT301 Cell Injection infusion. | Other | BCT301 Cell Injection therapy group |
Primary outcome
The safety and tolerability of BCT301 Cell Injection in patients with refractory/recurrent IgG4-RD.
Time frame: 28 days after BCT301 Cell Injection infusion
The occurrence of cell-infusion-related adverse events within 28 days after BCT301 Cell Injection infusion, with special emphasis on cell-therapy-specific adverse reactions such as CRS and ICANS.
6 secondary outcomes
The change in IgG4-RD RI from baseline at 180 days after BCT301 Cell Injection infusion.
Time frame: 180 days after BCT301 Cell Injection infusion.
IgG4-RD RI response rate (decrease ≥ 2 points from baseline) at 90 and 180 days after BCT301 Cell Injection infusion.
Time frame: 90, 180 days after BCT301 Cell Injection infusion.
IgG4-RD complete remission rate at 180 and 360 days after BCT301 Cell Injection infusion.
Time frame: 180 and 360 days after BCT301 Cell Injection infusion.
Proportion of patients with relapse after remission at 90, 180, and 360 days after BCT301 Cell Injection infusion.
Time frame: 90, 180, and 360 days after BCT301 Cell Injection infusion.
Changes in IgG4 levels at 90, 180, and 360 days after BCT301 Cell Injection infusion.
Time frame: 90, 180, and 360 days after BCT301 Cell Injection infusion.
Physician Global Assessment (PhGA) and Patient Global Assessment (PtGA) compared with baseline.
Time frame: 90, 180, and 360 days after BCT301 Cell Injection infusion.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for IgG4-related Disease
RecruitingPhase 1
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
RecruitingPhase 3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Immunoglobulin G4 Related Disease
Not yet recruitingPhase 2
Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
IgG4 Related Disease
RecruitingPhase 1/2
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
IgG4 Related Disease
Enrolling by invitationObservational study
Comparative Autoantibody and Immunologic Cell Marker Study
Autoimmune Diseases, Lupus Erythematosus, Systemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing BCT301 Cell Injection in people with IgG4-related Disease, run by Peking University Third Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jinxia Zhao, MD (8610 82265699, zhao-jinxia@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The safety and tolerability of BCT301 Cell Injection in patients with refractory/recurrent IgG4-RD. (time frame: 28 days after BCT301 Cell Injection infusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.